Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. USO
2. DHR
3. NVDA
4. SPY
5. AMD
6. GM
7. SMCI
8. GOOGL
9. TSLA
10. NOW

Go back to Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
(NASDAQ: VRDN) Delayed: 19.17 -0.01 (0.05%)
Previous Close $19.18    52 Week High $ 
Open $18.94    52 Week Low $ 
Day High $19.39    P/E N/A 
Day Low $18.73    EPS $ 
Volume 2,622,774